Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Common Equity (2019 - 2025)

Historic Common Equity for IDEAYA Biosciences (IDYA) over the last 7 years, with Q3 2025 value amounting to $1.1 billion.

  • IDEAYA Biosciences' Common Equity fell 748.75% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year decrease of 748.75%. This contributed to the annual value of $1.1 billion for FY2024, which is 7053.04% up from last year.
  • IDEAYA Biosciences' Common Equity amounted to $1.1 billion in Q3 2025, which was down 748.75% from $959.7 million recorded in Q2 2025.
  • IDEAYA Biosciences' 5-year Common Equity high stood at $1.2 billion for Q3 2024, and its period low was $233.1 million during Q1 2021.
  • Over the past 5 years, IDEAYA Biosciences' median Common Equity value was $501.6 million (recorded in 2023), while the average stood at $606.1 million.
  • Its Common Equity has fluctuated over the past 5 years, first surged by 18019.26% in 2024, then tumbled by 748.75% in 2025.
  • IDEAYA Biosciences' Common Equity (Quarter) stood at $301.5 million in 2021, then grew by 15.9% to $349.5 million in 2022, then skyrocketed by 77.73% to $621.1 million in 2023, then surged by 70.53% to $1.1 billion in 2024, then rose by 3.11% to $1.1 billion in 2025.
  • Its last three reported values are $1.1 billion in Q3 2025, $959.7 million for Q2 2025, and $1.0 billion during Q1 2025.